Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma.
Adrenocortical carcinoma
Clinicopathology
Cushing’s syndrome
Steroid metabolites
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
13
07
2020
accepted:
16
11
2020
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
24
8
2021
Statut:
epublish
Résumé
Approximately 60% of adrenocortical carcinomas (ACC) are functional, and Cushing's syndrome is the most frequent diagnosis that has been revealed to have a particularly poor prognosis. Since 30% of ACC present steroid hormone-producing disorganization, measurement of steroid metabolites in suspected ACC is recommended. Previous reports demonstrated that steroid hormone precursors or their urine metabolites, which can be assessed using liquid chromatography tandem mass spectrometry (LC-MS/MS) or gas chromatography mass spectrometry (GC-MS) respectively, are useful for distinguishing ACC from cortisol-producing adenomas (CPA); however, despite high precision, LC-MS/MS and GC-MS require a highly trained team, are expensive and have limited capacity. Here, we examined 12 serum steroid metabolites using an immunoassay, which is a more rapid and less costly method than LC-MS/MS, in cortisol-producing ACC and CPA. Further, the correlation of each steroid metabolite to the classification stage and pathological status in ACC was analyzed. Reflecting disorganized steroidogenesis, the immunoassay revealed that all basal levels of steroid precursors were significantly increased in cortisol-producing ACC compared to CPA; in particular, 17-hydroxypregnenolone (glucocorticoid and androgen precursor) and 11-deoxycorticosterone (mineralocorticoid precursor) showed a large area under the ROC curve with high sensitivity and specificity when setting the cut-off at 1.78 ng/ml and 0.4 mg/ml, respectively. Additionally, a combination of androstenedione and DHEAS also showed high specificity with high accuracy. In cortisol-producing ACC, 11-deoxycortisol (glucocorticoid precursor) showed significant positive correlations with predictive prognostic factors used in ENSAT classification, while testosterone showed significant positive correlations to the Ki67-index in both men and women. Less expensive and more widely available RIA and ECLIA may also biochemically distinguish ACC from CPA and may predict the clinicopathological features of ACC.
Sections du résumé
BACKGROUND
BACKGROUND
Approximately 60% of adrenocortical carcinomas (ACC) are functional, and Cushing's syndrome is the most frequent diagnosis that has been revealed to have a particularly poor prognosis. Since 30% of ACC present steroid hormone-producing disorganization, measurement of steroid metabolites in suspected ACC is recommended. Previous reports demonstrated that steroid hormone precursors or their urine metabolites, which can be assessed using liquid chromatography tandem mass spectrometry (LC-MS/MS) or gas chromatography mass spectrometry (GC-MS) respectively, are useful for distinguishing ACC from cortisol-producing adenomas (CPA); however, despite high precision, LC-MS/MS and GC-MS require a highly trained team, are expensive and have limited capacity.
METHODS
METHODS
Here, we examined 12 serum steroid metabolites using an immunoassay, which is a more rapid and less costly method than LC-MS/MS, in cortisol-producing ACC and CPA. Further, the correlation of each steroid metabolite to the classification stage and pathological status in ACC was analyzed.
RESULTS
RESULTS
Reflecting disorganized steroidogenesis, the immunoassay revealed that all basal levels of steroid precursors were significantly increased in cortisol-producing ACC compared to CPA; in particular, 17-hydroxypregnenolone (glucocorticoid and androgen precursor) and 11-deoxycorticosterone (mineralocorticoid precursor) showed a large area under the ROC curve with high sensitivity and specificity when setting the cut-off at 1.78 ng/ml and 0.4 mg/ml, respectively. Additionally, a combination of androstenedione and DHEAS also showed high specificity with high accuracy. In cortisol-producing ACC, 11-deoxycortisol (glucocorticoid precursor) showed significant positive correlations with predictive prognostic factors used in ENSAT classification, while testosterone showed significant positive correlations to the Ki67-index in both men and women.
CONCLUSION
CONCLUSIONS
Less expensive and more widely available RIA and ECLIA may also biochemically distinguish ACC from CPA and may predict the clinicopathological features of ACC.
Identifiants
pubmed: 33228607
doi: 10.1186/s12902-020-00652-y
pii: 10.1186/s12902-020-00652-y
pmc: PMC7686776
doi:
Substances chimiques
Biomarkers
0
Steroids
0
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173Références
Minerva Endocrinol. 2019 Mar;44(1):19-24
pubmed: 29905434
J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602
pubmed: 14671138
J Clin Endocrinol Metab. 2015 Jun;100(6):2165-70
pubmed: 25850026
World J Surg. 2001 Jul;25(7):891-7
pubmed: 11572030
Eur J Endocrinol. 2016 Aug;175(2):R65-80
pubmed: 27257146
J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5
pubmed: 16670169
Horm Cancer. 2015 Aug;6(4):168-75
pubmed: 25985881
Lancet. 2006 May 13;367(9522):1605-17
pubmed: 16698415
Endocr Relat Cancer. 2011 Feb 23;18(2):R15-27
pubmed: 21208995
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107
Eur J Endocrinol. 2018 Dec 1;179(6):429-436
pubmed: 30325179
J Clin Endocrinol Metab. 2015 Sep;100(9):L88
pubmed: 26339748
Endocrinol Metab Clin North Am. 2015 Jun;44(2):399-410
pubmed: 26038208
J Clin Endocrinol Metab. 2015 Sep;100(9):L86-7
pubmed: 26339747
Endocr Pathol. 2006 Winter;17(4):345-54
pubmed: 17525483
Eur J Endocrinol. 2019 Feb 1;180(2):117-125
pubmed: 30481155
J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37
pubmed: 16551738
J Urol. 1995 Dec;154(6):2004-9
pubmed: 7500445
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31665449
Endocr Relat Cancer. 2007 Mar;14(1):13-28
pubmed: 17395972
Lancet Diabetes Endocrinol. 2020 Sep;8(9):773-781
pubmed: 32711725
Am J Surg Pathol. 1989 Mar;13(3):202-6
pubmed: 2919718
J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84
pubmed: 21917861
Clin Chem. 2017 Dec;63(12):1836-1846
pubmed: 28904054
J Urol. 2003 Jan;169(1):5-11
pubmed: 12478091
Endocrinol Diabetes Metab Case Rep. 2019 Nov 28;2019:
pubmed: 31778357
J Clin Endocrinol Metab. 2013 Oct;98(10):3971-3
pubmed: 24098015
Curr Opin Endocrinol Diabetes Obes. 2017 Jun;24(3):200-207
pubmed: 28234802
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Eur J Cancer. 2010 Mar;46(4):713-9
pubmed: 20044246
Clin Chem. 2017 Dec;63(12):1824-1835
pubmed: 28814383
Am J Surg Pathol. 2002 Dec;26(12):1612-9
pubmed: 12459628
Horm Cancer. 2016 Dec;7(5-6):327-335
pubmed: 27370636